3 ms·
Derek Lowe is mentioning remdisivir as one of the leading candidates for COVID-19 therapy here on March 6th, before the HCQ brouhaha starts: https://blogs.scien
by jcranmer 6y ago
Derek Lowe is mentioning remdisivir as one of the leading candidates for COVID-19 therapy here on March 6th, before the HCQ brouhaha starts: https://blogs.sciencemag.org/pipeline/archives/2020/03/06/covid-19-small-molecule-therapies-reviewed https://blogs.sciencemag.org/pipeline/archives/2020/03/06/co... (he also mentions chloroquine as a protocol under investigation).
For those unfamiliar: Derek Lowe is a drug discovery chemist who writes a well-known blog on drug discovery and other chemical topics (most notably the "Things I Won't Work With" series, which covers nasty chemicals like ClF₃ or C₂N₁₄), which has of course been dominated by COVID-19 in 2020.
- hef19898 6y agoMarch < October. I assume we all learned a lot in the couple months.
- jcranmer 6y agoThe claim being raised here is that remdesivir was a known-to-be-failed treatment that was only trotted out after the miracle hydroxychloroquine cure came out, with the implication being that it's an attempt to suppress HCQ. That remdesivir was publicly considered a leading candidate after its supposed proof-of-failure and before the HCQ treatment was publicized rather demolishes whatever implication of conspiracy is being considered.
- tboyd47 6y ago"Leading candidate" still doesn't mean it's not going to be a flop. If you look at what the press and medical experts were saying about Remdesivir throughout this period, it was lukewarm at best. But they were saying it so loudly and repetitively that it makes me wonder if the point wasn't to sell Remdesivir per se but just to drown out other news. Even if HCQ is useless, that doesn't preclude the notion that it was seen as a threat to Big Pharma's bottom line in mid-March. Of course it was. Like I said earlier, it's cheap and out-of-patent. I think all of us in this thread are circling around the same understanding when it comes to the facts of the matter. But where we differ is that I'm much more open to the idea that the authorities could have self-serving motives in play besides keeping us safe. The idea that policymakers and even scientists may be corrupt is not far-fetched. We have to try to keep an eye on them. Have a great day and thanks for the debate.
- tboyd47 6y agoThanks. That seemed to contradict my reading, but then when I clicked into the BioCentury article he referenced, I saw this: > By Selina Koch, Executive Editor | Feb 27, 2020 | 7:56 PM EST > Editor's note: Updated on Mar 17, 2020 at 9:30 PM EDT March 17th again. I'd love to know what edit was made at 9:30 PM on the same day the HCQ announcement came out. The Wayback Machine didn't find anything.
- jcranmer 6y agoThe original text by Derek Lowe is available at https://web.archive.org/web/20200311135536/https://blogs.sciencemag.org/pipeline/archives/2020/03/06/covid-19-small-molecule-therapies-reviewed https://web.archive.org/web/20200311135536/https://blogs.sci... And Derek Lowe's summary was unchanged in his edit: > My personal opinion is that I like the chances of this drug [remdesivir] more than anything else on this list, but it’s still unlikely to be a game-changer.
- tboyd47 6y agoI was talking about the BioCentury article, not his article. Anyway, thanks again for finding that, because it's a valid counterpoint.
- tchalla 6y agoLowe talks about it being "most advanced" not a "leading candidate". Lowe's opinion on it is > My personal opinion is that I like the chances of this drug more than anything else on this list, but it’s still unlikely to be a game-changer.